Bispecific T-cell engagers in oral cancer immunotherapy

Bispecific T-cell engagers in oral cancer immunotherapy

Saved in:

Bibliographic Details
Main Author:	Veeraraghavan Vishnu Priya
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Series:	Oral Oncology Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772906024001018
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Promoting oral cancer awareness in LGBTQ+ communities - Diversity in oral health
by: Gayathri Rengasamy, et al.
Published: (2024-09-01)

Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
by: Amelia C. McCue, et al.
Published: (2024-12-01)

Nanoengineered chemotherapy - A novel therapeutic strategy in oral cancer
by: Gayathri Rengasamy, et al.
Published: (2024-06-01)

Current advances in bispecific T cell–engaging therapies
by: Emmanuel Owusu Ansah, et al.
Published: (2025-04-01)

Environmental pollution and its link to heightened oral cancer risk: A rapidly growing public health issue
by: Vishnu Priya Veeraraghavan, et al.
Published: (2024-06-01)

Emerging therapeutic targets in oral squamous cell carcinoma: Insights from genetic alterations
by: Santosh R. Patil, et al.
Published: (2024-06-01)

Can vimentin be an emerging early detection molecular biomarker in oral squamous cell carcinoma?
by: Kalaiselvi Krishnamoorthy, et al.
Published: (2024-06-01)

CDK5RAP2: A potential prognostication biomarker for oral squamous cell carcinoma?
by: Benson Paul, et al.
Published: (2024-06-01)

Exploring the Nanopore principle based portable device in oral cancer can serve as potential diagnostic tool facilitating focused treatment
by: Arthisri Anandhi Sekar, et al.
Published: (2024-03-01)

Revolutionizing precision medicine in oral squamous cell carcinoma: Harnessing 3D in vitro models for translation
by: Nitesh Buldak, et al.
Published: (2024-09-01)

Unveiling the anti-cancer mechanisms of calotropin: Insights into cell growth inhibition, cell cycle arrest, and metabolic regulation in human oral squamous carcinoma cells (HSC-3)
by: Selvaraj Jayaraman, et al.
Published: (2023-11-01)

Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies
by: Madelyn Espinosa-Cotton, et al.
Published: (2020-10-01)

Unlocking the potential of beta sitosterol: Augmenting the suppression of oral cancer cells through extrinsic and intrinsic signalling mechanisms
by: Selvaraj Jayaraman, et al.
Published: (2023-12-01)

T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer
by: S. M. Greiner, et al.
Published: (2025-07-01)

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma
by: Andrée-Anne Pelland, et al.
Published: (2025-04-01)

Manufacturability and functionality assessment of different formats of T-cell engaging bispecific antibodies
by: Han Ping Loh, et al.
Published: (2023-12-01)

Nuclear factor Erythroid 2-related factor (Nrf2): A potential therapeutic target for oral cancer - Molecular insights
by: Kaviyarasi Renu, et al.
Published: (2024-06-01)

Innovative strategies for T cell engagers for cancer immunotherapy
by: Cristina Bergamaschi, et al.
Published: (2025-12-01)

Natural killer cell engagers for cancer immunotherapy
by: Shahryar Khoshtinat Nikkhoi, et al.
Published: (2025-01-01)

eIg-based bispecific T-cell engagers targeting EGFR: Format matters
by: Lennart Kühl, et al.
Published: (2023-12-01)

Oncolytic virotherapy in head and neck cancer: A hope?
by: Vishnu Priya Veeraraghavan, et al.
Published: (2024-03-01)

Expression and treatment of ROR1+ cells with bispecific T-cell engagers in pediatric acute lymphoblastic leukemia
by: Paraskevi Diamanti, et al.
Published: (2025-07-01)

Safety and Practicalities of Bispecific T‐Cell Engager Administration in a District General Hospital Setting
by: Benjamin Lau, et al.
Published: (2025-06-01)

“Comment on the “the impact of emotional distress on suicidal ideation in head and neck cancer patients: A review”
by: Gayathri Rengasamy, et al.
Published: (2024-09-01)

Format-tuning of in vivo-launched bispecific T cell engager enhances efficacy against renal cell carcinoma
by: Carl H June, et al.
Published: (2024-06-01)

Anticancer effect of Moringa oleifera in oral squamous cell carcinoma: a systematic review
by: Chandini Rajkumar, et al.
Published: (2024-11-01)

Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen.
by: Gargi Das, et al.
Published: (2025-01-01)

Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment
by: Hyukmin In, et al.
Published: (2025-02-01)

Targeted therapy: Role of liposome-based drug delivery in advancing oral cancer treatment
by: Meenakshi Sundari Rajendran, et al.
Published: (2024-06-01)

Osteopontin in oral squamous cell carcinoma: A multifaceted player in tumor development and prognosis
by: Hema Suryawanshi, et al.
Published: (2024-06-01)

Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma
by: Shannon A Kreuser, et al.
Published: (2020-10-01)

Structure-Based In Silico Drug Design and Docking Studies of Plant Phytochemicals as Fibroblast Growth Factor Receptor Inhibitors in Oral Squamous Cell Carcinoma
by: B. Dharshini, et al.
Published: (2025-01-01)

A novel bispecific aptamer targeting LAG3 and HER2 enhances T cell-mediated immunotherapy against HER2-positive cancer cells
by: Rui Guo, et al.
Published: (2025-07-01)

Novel strategy for tumor immunotherapy using FITC-folate bispecific adapter bridged CAR immune cell cocktails
by: Bin Liu, et al.
Published: (2025-10-01)

Development of a T cell engaging bispecific antibody targeting long non-coding RNA PVT1
by: Hirotaka Kato, et al.
Published: (2025-03-01)

A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer
by: Brian C. Avanzino, et al.
Published: (2022-12-01)

Immunotherapy in Multiple Myeloma: Recent Developments in Monoclonal Antibodies, Bispecifics and Antibody-Drug Conjugates
by: Rouven Müller
Published: (2024-12-01)

The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS
by: Nanni Schmitt, et al.
Published: (2025-08-01)

A CD1c lipid agnostic T cell receptor bispecific engager redirects T cells against CD1c+ cells
by: Rita Szoke-Kovacs, et al.
Published: (2025-07-01)

Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice
by: Ge Yang, et al.
Published: (2024-03-01)